Drug Patents owned by Apil
1. List of Actonel drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7192938 | APIL | Method of treatment using bisphosphonic acid |
May, 2023
(26 days ago) | |
| US7718634 | APIL | Method of treatment using bisphosphonic acid |
May, 2023
(26 days ago) | |
|
US7192938 (Pediatric) | APIL | Method of treatment using bisphosphonic acid |
Nov, 2023
(5 months from now) | |
|
US7718634 (Pediatric) | APIL | Method of treatment using bisphosphonic acid |
Nov, 2023
(5 months from now) | |
Drugs and Companies using RISEDRONATE SODIUM ingredient
Market Authorisation Date: 27 March, 1998
Treatment: Prevention and treatment of osteoporosis; Treatment of osteoporosis in postmenopausal women
Dosage: TABLET;ORAL
ACTONEL family patents
7
Korea, Republic of
6
European Union
5
United States
5
Japan
3
Australia
2
Spain
2
Malaysia
2
Denmark
2
Poland
2
China
2
Russia
2
Canada
2
Argentina
2
Norway
2
New Zealand
2
Cyprus
2
Israel
2
Portugal
2
Slovenia
1
Uruguay
1
Panama
1
Austria
1
Hong Kong
1
Germany
1
Brazil
1
Croatia
1
Guatemala
1
Peru
1
Taiwan
1
Mexico
1
Ecuador
1
South Africa
2. List of Atelvia drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8246989 | APIL | Dosage forms of bisphosphonates |
Jan, 2026
(2 years from now) | |
| US7645460 | APIL | Dosage forms of risedronate |
Jan, 2028
(4 years from now) | |
| US7645459 | APIL | Dosage forms of bisphosphonates |
Jan, 2028
(4 years from now) | |
Drugs and Companies using RISEDRONATE SODIUM ingredient
Market Authorisation Date: 08 October, 2010
Treatment: Treatment of osteoporosis in postmenopausal women
Dosage: TABLET, DELAYED RELEASE;ORAL
ATELVIA family patents
19
United States
7
Korea, Republic of
5
Japan
4
China
4
European Union
3
Spain
3
Canada
3
New Zealand
3
Portugal
3
Australia
2
Denmark
2
Poland
2
Russia
2
Brazil
2
Morocco
2
Argentina
2
Norway
2
San Marino
2
Israel
2
Taiwan
2
Mexico
1
Austria
1
Hong Kong
1
Malaysia
1
India
1
RS
1
Germany
1
Croatia
1
Cyprus
1
Peru
1
South Africa
1
Slovenia
1
Hungary
3. List of Femtrace drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7572779 | APIL | Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
Oct, 2025
(2 years from now) | |
Drugs and Companies using ESTRADIOL ACETATE ingredient
Market Authorisation Date: 20 August, 2004
Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause
Dosage: TABLET;ORAL
FEMTRACE family patents
4
United States
1
New Zealand
1
China
1
Mexico
1
Israel
1
Canada
1
Norway
1
Japan
1
Australia
1
European Union
4. List of Lo Loestrin Fe drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7704984 | APIL | Extended estrogen dosing contraceptive regimen |
Feb, 2029
(5 years from now) | |
Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient
Market Authorisation Date: 21 October, 2010
Treatment: Lo loestrin fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception
Dosage: TABLET;ORAL
LO LOESTRIN FE family patents
3
United States
2
China
2
European Union
1
Hong Kong
1
Israel
1
Canada
1
Mexico
5. List of Lo Minastrin Fe drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7704984 | APIL | Extended estrogen dosing contraceptive regimen |
Feb, 2029
(5 years from now) | |
Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient
Market Authorisation Date: 24 July, 2013
Treatment: Prevention of pregnancy
Dosage: TABLET, CHEWABLE, TABLET;ORAL
LO MINASTRIN FE family patents
3
United States
2
China
2
European Union
1
Hong Kong
1
Israel
1
Canada
1
Mexico
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic